Company Overview

Zymeworks Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of multifunctional antibody-based therapeutics for the treatment of cancer and other serious diseases. The company operates within the biotechnology and pharmaceutical industries, with a core emphasis on engineered biologics designed to address complex disease biology. Zymeworks’ primary value proposition lies in its proprietary antibody engineering technologies, which enable the creation of differentiated therapeutic candidates that can engage multiple disease pathways simultaneously.

Founded in 2003, Zymeworks evolved from a technology-focused platform company into a therapeutics-driven organization with an expanding clinical pipeline. Over time, the company shifted its strategy from primarily partnering its technology to advancing wholly owned drug candidates while selectively maintaining strategic collaborations. Its lead product candidates target oncology indications with significant unmet medical need, positioning the company within the high-value segment of precision cancer therapeutics.

Business Operations

Zymeworks generates value through the research and development of novel biologic drug candidates using its proprietary platforms, including Azymetric™ and EFECT™ antibody engineering technologies. The company’s operations are organized around the discovery, preclinical development, and clinical advancement of antibody-based therapeutics, with revenues historically derived from collaboration agreements, milestone payments, and licensing arrangements rather than product sales.

The company conducts operations primarily in North America, with research and development activities supported by internal scientific teams and external contract research organizations. Zymeworks has entered into multiple strategic partnerships with large pharmaceutical companies, under which partners may develop and commercialize product candidates using Zymeworks’ technologies while the company retains rights to certain programs and receives upfront payments, milestones, and potential royalties.

Strategic Position & Investments

Zymeworks’ strategic direction centers on advancing its wholly owned oncology pipeline while maintaining financial flexibility through disciplined capital allocation and selective partnering. The company has invested heavily in the clinical development of its lead bispecific antibody programs, particularly in solid tumor indications, while streamlining its portfolio to prioritize assets with the strongest clinical and commercial potential.

In parallel, Zymeworks has historically formed alliances with global pharmaceutical companies to validate its technology platforms and extend its reach into multiple therapeutic areas. The company continues to evaluate opportunities in emerging biologic modalities and next-generation antibody formats, leveraging its established engineering capabilities to remain competitive in the evolving oncology landscape.

Geographic Footprint

Zymeworks is headquartered in Canada, with principal offices in Vancouver, British Columbia, and significant operations in the United States, including research and administrative functions. Its operational footprint supports clinical development activities that span multiple countries, reflecting the global nature of modern oncology trials.

Through its partnerships and clinical programs, the company maintains an international presence across North America, Europe, and parts of Asia-Pacific, primarily via clinical trial sites and collaborator-led development activities. While Zymeworks does not maintain large commercial operations globally, its strategic collaborations provide international reach and development influence.

Leadership & Governance

Zymeworks is led by an executive team with experience across biotechnology, pharmaceuticals, and clinical development, emphasizing scientific rigor, disciplined execution, and long-term value creation. The leadership team guides the company’s transition from a platform-based organization to a focused clinical-stage biopharmaceutical company with potential future commercialization ambitions.

Key executives include:

• Kenneth Galbraith – President and Chief Executive Officer
• Paul Moore – Chief Financial Officer
• Roseann Benson – Chief Legal Officer and Corporate Secretary
• Jeffrey Smith – Chief Development Officer
• Sharon Shacham – Chief Scientific Officer

The company’s governance framework emphasizes oversight of clinical risk, capital management, and strategic prioritization, consistent with its status as a publicly traded biotechnology company.